Fudan University: Esophageal Neoplasms trials

The registry lists 28 Esophageal Neoplasms studies with Fudan University as lead sponsor. 15 are open to participants now and 0 have results posted.

Phase 1 1Phase 2 9Phase 3 5No phase 14(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Prospective Study of Tumor-specific Tpex in Negative Lymph Nodes for Predicting Pathological Complete Response to Neoadjuvant PD 1 Therapy in Esophageal CancerNot yet recruitingNCT07573397
• Tpex Subsets in Negative Tumor Draining Lymph Nodes for Predicting the Efficacy of PD 1 Inhibitors in Advanced or Recurrent Esophageal Squamous Cell CarcinomaNot yet recruitingNCT07533357
• Omega-3 Fatty Acids With PD-1 Inhibitors in Advanced Esophageal CancerRecruitingNCT07272382Not applicable
• Incidence of 106TBL Lymph Node MetastasisRecruitingNCT07165210
• Incidence of 107 Lymph Node MetastasisRecruitingNCT07165184
• CCRT Followed by PD-1 Inhibitor Maintenance Therapy in Locally Advanced ESCCRecruitingNCT06964568Phase 3
• Precision Palliative Care for Patients With Advanced Esophageal CancerRecruitingNCT06787313
• TDLN-sparing RT Plus Immunotherapy and Chemotherapy in Locally Advanced ESCCRecruitingNCT06676449Phase 3
• Study of The Second-line Treatment of Advanced Gastric / Gastroesophageal Junction Adenocarcinoma With Cadonilimab and Fruquintinib Combined With Paclitaxel-albuminRecruitingNCT06406426Phase 2
• The Study on the Mechanism of Radiotherapy-elicited Immune ResponseRecruitingNCT06393140
• A Study of PD-1 Inhibitors Combined With Fruquintinib and Chemotherapy in First-line Treatment of HER2-negative Advanced G/GEJ CancerRecruitingNCT06158919Not applicable
• Radiotherapy + Chemoimmunotherapy Followed by Surgery in Patients With Limited Metastatic Gastric or GEJ CancerRecruitingNCT06121700Phase 2
• Study of The Second-line Treatment of Advanced Gastric / Gastroesophageal Junction Adenocarcinoma With Envafolimab and Lenvatinib Combined With Paclitaxel-albuminEnrolling by invitationNCT06030934Phase 2
• Value of Pleural Lavage Cytology in Resectable Esophageal Carcinoma Eastern Cooperative Thoracic Oncology Projects 2005, ECTOP-2005)RecruitingNCT05443841
• Comparing 61.2 Gy Radiotherapy Dose Versus 50.4 Gy Radiotherapy Dose for Locally Advanced Esophageal CarcinomaRecruitingNCT03790553Phase 3
• Efficacy of Tirellizumab Combined With Oral, Intravenous and Abdominal Chemotherapy in Peritoneal Metastatic Gastric/Gastroesophageal Junction AdenocarcinomaActive, not recruitingNCT06914687Phase 2
• Cola Ingestion for Esophageal Bolus ImpactionActive, not recruitingNCT06652620Not applicable
• Primary Tumor Burden Score:A Novel Staging Parameter for ESCC After nCRTCompletedNCT05839002
• Phase II Study of Postoperative Concurrent Chemoradiotherapy for Esophageal Squamous Cell Carcinoma (ESO- Shanghai 17)Active, not recruitingNCT04764227Phase 2
• Genomic Study of Relapse Esophageal Cancer After RadiotherapyStatus unknownNCT04694391
• Efficacy and Safety of Apatinib for Recurrent or Metastatic Esophageal Squamous Cell CarcinomaCompletedNCT03274011Phase 2
• Efficacy of Nasogastric Tube Application in Postoperative Care of EsophagectomyStatus unknownNCT03273686Phase 3
• Dose Escalation by Boosting Radiation Dose Within the Primary Tumor Using 18FDG-PET/CT for Unresectable Thoracic Esophageal CancerStatus unknownNCT01843049Phase 1/2
• Esophagectomy:Three-field Versus Two-field Lymphadenectomy (ECTOP-2002)CompletedNCT01807936Not applicable
• Impact on Quality of Life in Patients Undergoing Total Gastrectomy or Proximal Gastrectomy for Adenocarcinoma of Esophagogastric JunctionStatus unknownNCT01697917Phase 3
• Study on FOLFOX6 as First-line Therapy to Treat Recurrent or Metastatic Esophageal CancerCompletedNCT01605305Phase 2
• Health-related Quality of Life of Patients With Esophageal Cancer After SurgeryStatus unknownNCT01349517Phase 2
• Esophagectomy: Sweet Versus Ivor-Lewis (ESVIL) (ECTOP-2001)CompletedNCT01047111Not applicable